General Information of Drug (ID: DM9WC1T)

Drug Name
NK3201 Drug Info
Synonyms
NK-3201; NK3201; 204460-24-2; NK 3201; (2-(5-Formylamino-6-oxo-2-phenyl-1,6-dihydropyrimidine-1-yl)-N-(3,4-dioxo-1-phenyl-7-(2-pyridyloxy)-2-heptyl)acetamide); N-(3,4-dioxo-1-phenyl-7-pyridin-2-yloxyheptan-2-yl)-2-(5-formamido-6-oxo-2-phenylpyrimidin-1-yl)acetamide; AC1Q5BUH; AC1L4U5M; GTPL6503; SCHEMBL4350497; CTK1A5741; AKOS030531107; LS-9646; n-[3,4-dioxo-1-phenyl-7-(pyridin-2-yloxy)heptan-2-yl]-2-[5-(formylamino)-6-oxo-2-phenylpyrimidin-1(6h)-yl]acetamide; KB-145958
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
213050
CAS Number
CAS 204460-24-2
TTD Drug ID
DM9WC1T

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Investigative Drug(s)
Drug(s) Targeting Chymase (CYM)
Drug Name Drug ID Indication ICD 11 Highest Status REF
SUN13834 DMPK34E Gram-positive bacterial infection 1B74-1G40 Phase 2 [3]
JNJ-10311795 DM7OTQS Chronic obstructive pulmonary disease CA22 Phase 2 [4]
ASB17061 DMNVU28 Atopic dermatitis EA80 Phase 2 [5]
BAY 11-42524 DM8SNEM Left ventricular dysfunction BD11 Phase 2 [6]
BAY 1142524 DMHKTGX Myocardial infarction BA41-BA43 Phase 2 [7]
2-(N-Morpholino)-Ethanesulfonic Acid DMZVHSB Discovery agent N.A. Investigative [8]
Benzylsulfinic Acid DM7XK28 Discovery agent N.A. Investigative [9]
KM-01221 DMG594K Cardiovascular disease BA00-BE2Z Investigative [10]
Y-40613 DM412IV Discovery agent N.A. Investigative [11]
Rac-2q DMD5TPH Discovery agent N.A. Investigative [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Chymase (CYM) TT8VUE0 CMA1_HUMAN Inhibitor [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6503).
2 Impact of chymase inhibitor on cardiac function and survival after myocardial infarction. Cardiovasc Res. 2003 Nov 1;60(2):413-20.
3 Oral chymase inhibitor SUN13834 ameliorates skin inflammation as well as pruritus in mouse model for atopic dermatitis.Eur J Pharmacol.2008 Dec 28;601(1-3):186-91.
4 Discovery of potent, selective, orally active, nonpeptide inhibitors of human mast cell chymase. J Med Chem. 2007 Apr 19;50(8):1727-30.
5 Immunology of atopic eczema: overcoming the Th1/Th2 paradigm. Allergy. 2013 Aug;68(8):974-82.
6 ClinicalTrials.gov (NCT02452515) A Single-blind Pilot Study to Investigate Safety and Tolerability of the Chymase Inhibitor BAY1142524 in Clinically Stable Patients With Left-ventricular Dysfunction.
7 Pharmacokinetics, Safety, and Tolerability of the Novel Chymase Inhibitor BAY 1142524 in Healthy Male Volunteers. Clin Pharmacol Drug Dev. 2019 May;8(4):467-479.
8 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
9 The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.
10 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2340).
11 Therapeutic potential of a specific chymase inhibitor in atopic dermatitis. Jpn J Pharmacol. 2002 Nov;90(3):214-7.
12 Identification of 6-substituted 4-arylsulfonyl-1,4-diazepane-2,5-diones as a novel scaffold for human chymase inhibitors. Bioorg Med Chem Lett. 2007 Jun 15;17(12):3431-4.